Persistence of hepatitis C virus traces after spontaneous resolution of hepatitis C

PLoS ONE

Volumn 10, Issue 10, 2015, Pages

  Chen, Annie Y ^a   Hoare, Matthew ^b,c   Shankar, Arun N ^c   Allison, Michael ^c   Alexander, Graeme J M ^c   Michalak, Tomasz I ^a  

^a MEMORIAL UNIVERSITY OF NEWFOUNDLAND   (Canada)

^b CANCER RESEARCH UK CAMBRIDGE RESEARCH INSTITUTE   (United Kingdom)

^c UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

TELAPREVIR; VIRUS RNA; OLIGOPEPTIDE;

ADULT; AGED; ARTICLE; BLOOD ANALYSIS; CLINICAL ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; FEMALE; FOLLOW UP; GENE SEQUENCE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN CELL; INCIDENCE; MALE; MIDDLE AGED; NUCLEOTIDE SEQUENCE; PERIPHERAL BLOOD MONONUCLEAR CELL; PERSISTENT INFECTION; PHYLOGENY; POINT MUTATION; REMISSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA EXTRACTION; SINGLE NUCLEOTIDE POLYMORPHISM; VIRUS DETECTION; VIRUS REPLICATION; BLOOD; HEPACIVIRUS; HEPATITIS C, CHRONIC; METABOLISM; MOLECULAR GENETICS; MONONUCLEAR CELL; RANDOMIZED CONTROLLED TRIAL; TIME FACTOR; VIROLOGY;

ADULT; AGED; BASE SEQUENCE; FEMALE; FOLLOW-UP STUDIES; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; LEUKOCYTES, MONONUCLEAR; MALE; MIDDLE AGED; MOLECULAR SEQUENCE DATA; OLIGOPEPTIDES; REMISSION, SPONTANEOUS; RNA, VIRAL; TIME FACTORS;

EID: 84949033011     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0140312     Document Type: Article

References (38)

1. WHO (2014) Hepatitis C Fact Sheet No, 164, Updated April 2014. Available: http://www.who.int/mediacentre/factsheets/fs164/en/.
2. Lavanchy D (2011) Evolving epidemiology of hepatitis C virus. Clin Microbiol Infect 17:107-115. doi: 10.1111/j.1469-0691.2010.03432.x PMID: 21091831
3. Pham TNQ, Mac Parland SA, Mulrooney PM, Cooksley H, Naoumov NV, Michalak TI (2004) Hepatitis C virus persistence after spontaneous or treatment-induced resolution of hepatitis C. J Virol 78: 5867-5874. PMID: 15140984
4. Radkowski M, Gallegos-Orozco JF, Jablonska J, Colby TV, Walewska-Zielecka B, Kubicka J, et al. (2005) Persistence of hepatitis C virus in patients successfully treated for chronic hepatitis C. Hepatol-ogy 41:106-114. PMID: 15619235
5. Castillo I, Rodriguez-Inigo E, Lopez-Alcorocho JM, Pardo M, Bartolome J, Carreno V (2006) Hepatitis C virus replicates in the liver of patients who have a sustained response to antiviral treatment. Clin Infect Dis 43:1277-1283. PMID: 17051492
6. Pham TNQ, Coffin CS, Michalak TI (2010) Occult hepatitis C virus infection: what does it mean? Liver Int 30: 502-511. doi: 10.1111/j.1478-3231.2009.02193.x PMID: 20070513
7. Shata MT, Tricoche N, Perkus M, Tom D, Brotman B, McCormack P, et al. (2003) Exposure to low doses of HCV induces cellular immune responses without consistently detectable viremia or seroconversion in chimpanzees. Virology 314: 601-616. PMID: 14554088
8. Katayama K, Kumagai J, Komiya Y, Mizui M, Yugi H, Kishimoto S, et al. (2004) Titration of hepatitis C virus in chimpanzees for determining the copy number required for transmission. Intervirology 47: 57-64. PMID: 15044837
9. Mac Parland SA, Pham TNQ, Guy CS, Michalak TI (2009) Hepatitis C virus persisting after clinically apparent sustained virological response to antiviral therapy retains infectivity in vitro. Hepatology 49: 1431-1441. doi: 10.1002/hep.22802 PMID: 19177592
10. Castillo I, Pardo M, Bartolome J, et al. (2004) Occult hepatitis B virus infection in patients in whom the etiology of persistently abnormal results of liver-function tests is unknown. J Infect Dis 189: 7-14. PMID: 14702147
11. Veerapu NS, Raghuraman S, Liang TJ, Heller T, Rehermann B (2011) Sporadic reappearance of minute amounts of hepatitis C virus RNA after successful therapy stimulates cellular immune responses. Gastroenterology 140: 676-685. doi: 10.1053/j.gastro.2010.10.048 PMID: 21040725
12. Pham TNQ, Coffin CS, Churchill ND, Urbanski SJ, Lee SS, Michalak TI (2012) Hepatitis C virus persistence after sustained virological response to antiviral therapy in patients with or without past exposure to hepatitis B virus. J Viral Hepat 19:103-111. doi: 10.1111/j.1365-2893.2011.01442.x PMID: 21699630
13. Chen AY, Zeremski M, Chauhan R, Jacobson IM, Talal AH, Michalak TI (2013) Persistence of hepatitis C virus during and after otherwise clinically successful treatment of chronic hepatitis C with standard pegylated interferon a-2b and ribavirin therapy. PLoS ONE 8: e80078. doi: 10.1371/journal.pone. 0080078 PMID: 24278242
14. Veerapu NS, Park S-H, Tully DC, Allen TM, Rehermann B (2014) Trace amounts of sporadically reappearing HCV RNA can cause infection. Gastroenterology 124: 3469-3478.
15. Pham TNQ, Mercer SE, Michalak TI (2009) Chronic hepatitis C and persistent occult hepatitis C virus infection are characterized by distinct immune cell cytokine expression profiles. J Viral Hepat 16: 547-556. doi: 10.1111/j.1365-2893.2009.01092.x PMID: 19215578
16. Pham TNQ, Mac Parland SA, Coffin CS, Lee SS, Bursey FR, Michalak TI (2005) Mitogen-induced upre-gulation of hepatitis C virus expression in human lymphoid cells. J Gen Virol 86: 657-666. PMID: 15722526
17. Bartolome J, Lopez-Alcorocho JM, Castillo I, Rodriguez-Inigo E, Quiroga JA, Palacios B, et al. (2007) Ultracentrifugation of serum samples allows detection of hepatitis C virus RNA in patients with occult hepatitis C. J Virol 81: 7710-7715. PMID: 17475654
18. Pham TNQ, King D, Mac Parland SA, McGrath JS, Reddy SB, Bursey FR, et al. (2008) Hepatitis Cvirus replicates in the same immune cell subsets in chronic hepatitis C and occult infection. Gastroenterology 134: 812-822. doi: 10.1053/j.gastro.2007.12.011 PMID: 18243182
19. Di Liberto G, Roque-Afonso A-M, Kara R, Ducoulombier D, Fallot G, Samuel D, et al. (2006) Clinical and therapeutic implications of hepatitis C virus compartmentalization. Gastroenterology 131: 76-84. PMID: 16831592
20. Sarhan MA, Pham TNQ, Chen AY, Michalak TI (2012) Hepatitis C virus infection of human T lymphocytes is mediated by CD5. J Virol 86: 3723-3735. doi: 10.1128/JVI.06956-11 PMID: 22278227
21. Coffin CS, Michalak TI (1999) Persistence of infectious hepadnavirus in the offspring of woodchuck mothers recovered from viral hepatitis. J Clin Invest 104: 203-212. PMID: 10411550
22. Carla CS, Mulrooney-Cousins PM, Osiowy C, van derMeer F, Nishikawa S, Michalak TI, et al. (2014) Virological characteristics of occult hepatitis B virus in a North American cohort of human immunodeficiency virus type 1-positive patients on dual active anti-HBV/HIV therapy. J Clin Virol 60: 347-353. doi: 10.1016/j.jcv.2014.04.021 PMID: 24881491
23. Lin K, Perni RB, Kwong AD, Lin C (2006) VX-950, a novel hepatitis C virus (HCV) NS3-4A protease inhibitor, exhibits potent antiviral activities in HCV replicon cells. Antimicrob Agents Chemother 50: 1813-1822. PMID: 16641454
24. Koziel MJ, Wong DKH, Dudley D, Houghton M, Walker BD (1997) Hepatitis C virus-specificT cell lymphocyte and T helper cell responses in seronegative persons. J Inf Dis 176: 859-866.
25. Cramp ME, Carucci P, Rossol S, Chokshi S, Maertens G, Williams R (1999) Hepatitis C virus (HCV) specific immune responses in anti-HCV positive patients without hepatitis C viraemia. Gut 44: 424-429. PMID: 10026332
26. Takaki A, Wise M, Maertens G, Depla E, Serfert U, Liebetrau A, etal (2000) Cellular immune responses persist and humoral responses decrease two decades after recovery from a single-source outbreak of hepatitis C. Nat Med 6: 578-582. PMID: 10802716
27. Michalak TI, Pasquinelli C, Guilhot S, Chisari FV(1994) Hepatitis B virus persistence after recovery from acute viral hepatitis. J Clin Invest 93: 230-239. PMID: 8282792
28. Raimondo G, Caccamo G, Filomia R, Pollicino T (2013) Occult HBV infection. Semin Immunopathol 35: 39-52. doi: 10.1007/s00281-012-0327-7 PMID: 22829332
29. Mulrooney-Cousins PM, Chauhan R, Churchill ND, Michalak TI (2014) Primary seronegative butmolec-ularly evident hepadnaviral infection engages liver and induces hepatocellular carcinoma in the wood-chuck model of hepatitis B. PLoS Path 10: e1004332.
30. Pham TNQ, Mulrooney-Cousins PM, Mercer SE, Mac Parland SA, Inglot M, Zalewska M, et al. (2007) Antagonistic expression of hepatitis C virus and alpha interferon in lymphoid cells during persistent occult infection. J Viral Hepat 14: 537-548. PMID: 17650287
31. Ducoulombier D, Roque-Afonso A-M, Di Liberto G, Penin F, Kara R, Richard Y, et al. (2004) Frequent compartmentalization of hepatitis C virus variants in circulating B cells and monocytes. Hepatology 39: 817-825. PMID: 14999702
32. Pal S, Sullivan DG, Kim S, Lai KK, Kae J, Cotler SJ, et al. (2006) Productive replication of hepatitis C virus in perihepatic lymph nodes in vivo: implications of HCV lymphotropism. Gastroenterology 130: 1107-1116. PMID: 16618405
33. Mac Parland SA, Pham TNQ, Gujar SA, Michalak TI (2006) De novo infection and propagation of wild-type hepatitis C virus in human T lymphocytes in vitro. J Gen Virol 87: 3577-3586. PMID: 17098973
34. Ciure A, Klenerman P, Hunziker L, Horvath E, Odermatt B, Ochsenbein AF, et al. (1999) Persistence of lymphocytic chriomeningitis virus at very low levels in immune mice. Proc Natl Acad Sci USA 96: 11964-11969. PMID: 10518559
35. Hoare M, Gelson WTH, Rushbrook SM, Curran MD, Woodall T, Coleman N, et al. (2008) Histological changes in HCV antibody-positive, HCV RNA-negative subjects suggest persistent virus infection. Hepatology 48:1737-1745. doi: 10.1002/hep.22484 PMID: 18925639
36. Kobayashi S, Takeda T, Enomoto M, Tamori A, Kawada N, Habu D, et al. (2007) Development of hepatocellular carcinoma in patients with chronic hepatitis C who had a sustained virological response to interferon therapy: a multicenter, retrospective cohort study of 1224 patients. Liver Intl 27:186-191.
37. Morgan TR, Ghany MG, Kim H-Y, Snow KK, Shiffman ML, De Santo JL, et al. (2010) Outcome of sustained virological responders with histologically advanced chronic hepatitis C. Hepatology 52: 833-844. doi: 10.1002/hep.23744 PMID: 20564351
38. van derMeer A, Veldt BJ, Field JJ, Wedemeyer H, Dufour J-F, Lammert F, et al. (2012) Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis. JAMA 308: 2584-2595. doi: 10.1001/jama.2012.144878 PMID: 23268517